OMAR Opioid Use Disorder

• Status: Recruiting
• Trial end date: 2025-12-15
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Yale University
• Collaborator: National Institute on Drug Abuse (NIDA)

Criteria

Inclusion Criteria:

• Able to provide informed consent

• Male and female 18 years and older

• DSM-5 diagnosis of opioid use disorder (for OUD group)

• Physically healthy i.e., no clinically unstable medical conditions

• Written informed consent and have capacity to consent and comply with study procedures

Exclusion Criteria:

• Current neuro-psychiatric illness or severe systemic disease (opioid use disorder is permitted in the OUD group).

• Presence of ferromagnetic metal in the body or heart pacemaker

• Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits

• Are claustrophobic